Article Information
PMID
Published By
Print ISSN
0258-851X
Online ISSN
1791-7549
History
- Received May 21, 2022
- Revision received June 8, 2022
- Accepted June 9, 2022
- Published online September 7, 2022.
Copyright & License
Copyright © 2022 The Author(s). Published by the International Institute of Anticancer Research. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0).
Author Information
- DIRK RADES1⇑,
- JASPAR WITTELER1,
- PETER TRILLENBERG2,
- DENISE OLBRICH3,
- STEVEN E. SCHILD4,
- SØREN TVILSTED5 and
- TROELS W. KJAER6
- 1Department of Radiation Oncology, University of Lübeck, Lübeck, Germany;
- 2Department of Neurology, University of Lübeck, Lübeck, Germany;
- 3The Centre for Clinical Trials Lübeck, University of Lübeck, Lübeck, Germany;
- 4Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, U.S.A.;
- 5Research Projects and Clinical Optimization, Zealand University Hospital, Køge, Denmark;
- 6Neurological Department, Zealand University Hospital, Roskilde, Denmark
- Correspondence to: Prof. Dirk Rades, MD, Department of Radiation Oncology, University of Lübeck, Ratzeburger Allee 160, 23562 Lübeck, Germany. Tel: +49 45150045401, Fax: +49 45150045404, e-mail: dirk.rades{at}uksh.de
